Drug-eluting stents for the treatment of coronary artery disease

Coronary artery disease - drug-eluting stents: review decision - June 2014 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 120 KB)

Coronary artery disease - drug-eluting stents: Review Proposal - April 2014 information

Appendix A - matrix of stakeholders (PDF 106 KB)

Appendix B - GE proposal paper - April 2014 (PDF 447 KB)

Coronary artery disease - drug-eluting stents: review decision - October 2010 information

Coronary artery disease - drug-eluting stents: appendix A decision paper considered by the Institute's Guidance Executive (PDF 30 KB)

NICE issues guidance on the use of drug-eluting stents for the treatment of coronary artery disease (PDF 40 KB)

TA152 Coronary artery disease - drug-eluting stents: review proposal August 2010 information

TA152 Coronary artery disease - drug-eluting stents: appendix A provisional matrix of stakeholders (MSWord 76 KB)

TA152 Coronary artery disease - drug-eluting stents: appendix B proposal paper presented to the Institute's Guidance Executive (PDF 105 KB)

TA152 Coronary artery disease - drug-eluting stents: appendix A provisional matrix of stakeholders (MSWord 76 KB)

TA152 Coronary artery disease - drug-eluting stents: appendix B proposal paper presented to the Institute's Guidance Executive (PDF 105 KB)

Review Decision - July 2009: Appendix 1: Proposal comment summary table (PDF 43 KB)

Review Decision - July 2009 information

Review Decision - July 2009: Appendix 1: Proposal comment summary table (PDF 43 KB)

Review proposal - May 2009 information

Review proposal - May 2009: appendix A, provisional matrix (PDF 33 KB)

Coronary artery disease - drug-eluting stents (part review of TA71): appeal information

Ischaemic heart disease - coronary artery stents (review): Appeal information

Ischaemic heart disease - coronary artery stents (review): Appeal announcement information

Ischaemic heart disease - coronary artery stents (review): Appeals received from Cordis 1 (PDF 146 KB)

Ischaemic heart disease - coronary artery stents (review): Appeals received from Cordis 2 (PDF 25 KB)

Ischaemic heart disease - coronary artery stents (review): Appeals received from Cordis 3 (PDF 121 KB)

Ischaemic heart disease - coronary artery stents: appeal decision (PDF 40 KB)

Ischaemic heart disease - coronary artery stents (review): Final Appraisal Determination (FAD)  information

Ischaemic heart disease - coronary artery stents (review): Final appraisal determination (PDF 150 KB)

Ischaemic heart disease - coronary artery stents (review): Addendum 7 (PDF 70 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation

Ischaemic heart disease - coronary artery stents (review): Response to public comments on the ACD (PDF 407 KB)

Response to Consultee and Commentator comments on the ACD (PDF 573 KB)

Consultee and commentator comments on the ACD

Abbott Laboratories Ltd (PDF 46 KB)

Action Heart (PDF 9.2 KB)

Boston Scientific (PDF 265 KB)

British Cardiovascular Industry Association (PDF 37 KB)

British Cardiovascular Society and British Cardiovascular Intervention Society (PDF 37 KB)

Cordis Corporation (PDF 194 KB)

Department of Health (PDF 28 KB)

Department of Health, Social Services and Public Safety for Northern Ireland (PDF 16 KB)

Kiwimed (PDF 19 KB)

Medtronic AVE (PDF 108 KB)

NHS Quality Improvement Scotland (PDF 20 KB)

Royal College of Nursing (PDF 20 KB)

NHS Supply Chain (PDF 38 KB)

Consultee and Commentator comments on the spreadsheets for agenda 5 and 6

Ischaemic heart disease - coronary artery stents (review): comments (PDF 165 KB)

Abbott Laboratories Ltd (PDF 165 KB)

Boston Scientific (PDF 18 KB)

British Cardiovascular Industry Association (PDF 64 KB)

British Cardiovascular Society and British Cardiovascular Intervention Society (PDF 37 KB)

Cordis Corporation (PDF 171 KB)

Medtronic AVE (PDF 27 KB)

Expert comments on the ACD

Clark (PDF 15 KB)

Bishop (PDF 17 KB)

Ischaemic heart disease - coronary artery stents (review): appraisal consultation

Ischaemic heart disease - coronary artery stents (review): Consultees/Commentators information

Ischaemic heart disease - coronary artery stents (review): appraisal consultation document information

Evaluation report

Overview (PDF 354 KB)

Coronary artery disease - drug-eluting stents: assessment report (PDF 1 MB)

Consultee and commentator comments on the assessment report

Association of British Health Care Industries (support letter) (PDF 34 KB)

Boston Scientific Ltd (PDF 106 KB)

British Cardiac Society and British Cardiovascular Intervention Society (joint response) (PDF 47 KB)

British Cardiovascular Industry Association (PDF 140 KB)

Cordis UK (PDF 212 KB)

Department of Health (PDF 43 KB)

EUCOMED (PDF 39 KB)

Kiwimed Ltd (PDF 15 KB)

Guidant Ltd (PDF 23 KB)

Medtronic Ltd (PDF 53 KB)

NHS Quality Improvement Scotland (PDF 21 KB)

Royal College of Nursing (PDF 16 KB)

Royal College of Physicians (PDF 42 KB)

Royal College of Physicians of Edinburgh (PDF 71 KB)

Society of Cardiothoracic Surgeons of GB and Ireland (PDF 35 KB)

Non-manufacturer submissions

British Cardiac Society and British Cardiovascular Intervention Society (PDF 47 KB)

Royal College of Physicians of Edinburgh (PDF 72 KB)

Manufacturer submissions (executive summary only)

Biosensors Europe (PDF 127 KB)

Biotronik UK Ltd (PDF 51 KB)

Boston Scientific Ltd (PDF 51 KB)

Cordis UK (PDF 119 KB)

Guidant Ltd (PDF 31 KB)

Kiwimed Ltd (PDF 90 KB)

Medtronic Ltd (PDF 53 KB)

Sorin Group UK Ltd (PDF 80 KB)

Expert written personal statements

Dr A H Gershlick, Consultant Cardiologist, Glenfield Hospital NHS Trust - nominated as a clinical expert by British Heart Foundation and British Cardiac Society (PDF 967 KB)

Mr Ron Box - nominated as a patient representative by Heart Care Partnership (PDF 27 KB)

Rev Dan Paterson, Retired Methodist Minister - nominated as a patient representative by Heart Care Partnership (PDF 35 KB)

Dr Martyn Thomas, President, British Cardiovascular Intervention Society - nominated as a clinical expert by British Cardiac Society, British Cardiovascular Intervention Society and Royal College of Physicians (PDF 18 KB)

Mrs Jill Bishop, Cardiac Catherter Lab Manager, British Association for Nursing in Cardiac Care - nominated as a clinical expert by British Association for Nursing in Cardiac Care (PDF 15 KB)

Dr Keith Oldroyd, Consultant Cardiologist, Western Infirmary - nominated as a clinical expert by NHS Quality Improvement Scotland (PDF 19 KB)

Mrs Liz Clark - nominated as a patient expert by the Heart Care Partnership (PDF 14 KB)

Additional work specification I (PDF 29 KB)

Additional work I (3' addendum) (PDF 295 KB)

Comments received from consultees and commentators on additional work I (3' addendum)

Boston Scientific Ltd (PDF 61 KB)

British Cardiovascular Industry Association (PDF 508 KB)

British Cardiac Society and British Cardiovascular Intervention Society (joint submission) (PDF 397 KB)

Cordis Corporation (PDF 300 KB)

Guidant Corporation (PDF 25 KB)

Medtronic (PDF 26 KB)

The Royal College of Physicians (PDF 43 KB)

The Royal College of Physicians Edinburgh (PDF 72 KB)

Additional sensitivity analyses post additional work (3? addendum supplement) (PDF 211 KB)

Additional work specification II (following FDA recommendations) (PDF 25 KB)

Additional sensitivity analyses (4' addendum - including clopidogrel costs) (PDF 77 KB)

Comments received from consultees and commentators on additional sensitivity analyses (post additional work [3?] and including clopidogrel costs [4'])

Abbott Vascular UK (PDF 100 KB)

Boston Scientific Ltd (PDF 170 KB)

Cordis Corporation (PDF 487 KB)

Department of Health (PDF 8.8 KB)

Medtronic AVE (PDF 1.81 MB)

Action Heart (PDF 25 KB)

British Cardiovascular Industry Association (PDF 95 KB)

British Cardiac Society and British Cardiovascular Intervention Society (joint submission) (PDF 591 KB)

The Royal College of Physicians (PDF 42 KB)

Additional sensitivity analyses (5' addendum - taking account ACS patients) (PDF 79 KB)

Addendum 6 (Sensitivity Analysis Tables for Drug-Eluting Stent Appraisal including Additional Use of Clopidogrel) (PDF 50 KB)

Ischaemic heart disease - coronary artery stents (review):Clarification of Addendum 6 (PDF 22 KB)

Project specification form (PDF 31 KB)

Final protocol (PDF 271 KB)

Final scope - Ischaemic heart disease - coronary artery stents (review) (PDF 95 KB)

Summary of consultee and commentator comments on the draft scope (PDF 183 KB)

Summary of consultee and commentator comments on the draft matrix (PDF 100 KB)

Archive: Provisional matrix of consultees and commentators (PDF 29 KB)

Archive: Draft scope information

Archive: Draft scope (PDF 30 KB)